Cited by 184Retinal Development and DisordersPhotoreceptor and optogenetics researchNeuroscience and Neural Engineering

Restoration of vision with ectopic expression of human rod opsin

Open access
Cehajic-Kapetanovic, Jasmina, Eleftheriou, Cyril, Allen, Annette E., Milosavljevic, Nina, Pienaar, Abigail, Bedford, Robert, Davis, Katherine E., Bishop, Paul N. +1 more·2015·Current Biology

Abstract

Many retinal dystrophies result in photoreceptor loss, but the inner retinal neurons can survive, making them potentially amenable to emerging optogenetic therapies. Here, we show that ectopically expressed human rod opsin, driven by either a non-selective or ON-bipolar cell-specific promoter, can function outside native photoreceptors and restore visual function in a mouse model of advanced retinal degeneration. Electrophysiological recordings from retinal explants and the visual thalamus revealed changes in firing (increases and decreases) induced by simple light pulses, luminance increases, and naturalistic movies in treated mice. These responses could be elicited at light intensities within the physiological range and substantially below those required by other optogenetic strategies. Mice with rod opsin expression driven by the ON-bipolar specific promoter displayed behavioral responses to increases in luminance, flicker, coarse spatial patterns, and elements of a natural movie at levels of contrast and illuminance (≈50-100 lux) typical of natural indoor environments. These data reveal that virally mediated ectopic expression of human rod opsin can restore vision under natural viewing conditions and at moderate light intensities. Given the inherent advantages in employing a human protein, the simplicity of this intervention, and the quality of vision restored, we suggest that rod opsin merits consideration as an optogenetic actuator for treating patients with advanced retinal degeneration.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cub.2015.07.029

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Pre-clinical optogenetic trials in mouse models of retinitis pigmentosa have restored basic visual function in blind animals, providing proof of principle.

    “Pre-clinical trials of optogenic therapies in murine models of retinitis pigmentosa have provided proof-of-principle in restoring basic visual function to blind animals, and human clinical trials are currently underway.”

    From Correcting visual loss by genetics and prosthetics (2020) · cites this paper as Cehajic-Kapetanovic 2015

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Cehajic-Kapetanovic, J., Eleftheriou, C., Allen, A. E., Milosavljevic, N., Pienaar, A., Bedford, R., Davis, K. E., Bishop, P. N., & Lucas, R. J.
Affiliations
  • University of Manchester (GB)
  • Manchester Academic Health Science Centre (GB)
Corresponding author
  • Bishop, Paul N.
  • Lucas, Robert J.
Venue
Current Biology
Publisher
Elsevier BV
Published
2015-08
Volume
25
Issue
16
Pages
2111-2122
ISSN
0960-9822 (ISSN-L)
OpenAlex
W1602094372
Cited by
184
References
36
Citations by year
2026: 8 · 2025: 15 · 2024: 10 · 2023: 22 · 2022: 31 · 2021: 18 · 2020: 18 · 2019: 21 · 2018: 9 · 2017: 19 · 2016: 9 · 2015: 3
FWCI
5.79
Type
journal article
Language
en
Open access
Locations
  • Current Biology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (submittedVersion)
Funders
  • Medical Research Council (MC_PC_13070)
  • Biotechnology and Biological Sciences Research Council (BB/K002252/1)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinal Development and Disorders
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Photoreceptor and optogenetics research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neural Engineering
Keywords
rod opsin, optogenetics, retinal degeneration, retinal dystrophy, ectopic expression, ON bipolar cells, photoreceptor loss, vision restoration, viral gene delivery, retinal explants, visual thalamus, photosensitivity, mouse model
MeSH terms
Ectopic Gene Expression, Animals, Humans, Retinal Degeneration, Rhodopsin, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review